PolyMedix is a clinical stage biotechnology company specializing in the development of pioneering small-molecule drugs that treat serious acute care conditions. The company’s pipeline of infectious disease and cardiovascular product candidates has been internally developed. The company’s lead infectious disease compound, PMX-30063, is the first drug from a new class of antibiotics designed to mimic natural human immunity. PolyMedix’s lead cardiovascular compound, PMX-60056, is designed to normalize blood clotting in patients taking heparin. For more information, visit the company’s Web site at www.polymedix.com

ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com

Let us hear your thoughts below: